Rapid Novor

We are excited to announce our next breakthrough for our REpAb® antibody discovery platform! Our team successfully sequenced a complex mixture of functional antibodies directly from the serum of a human patient after receiving a COVID-19 vaccine. This demonstrates the exciting progress in antibody discovery technologies to potentially bypass the need to work with animal models, DNA, and cells. To learn more about this exciting development, check out our press release here: https://hubs.li/Q01ShvSh0. #denovoseq #proteomics #bioinformatics #nextgenproteinseq #antibodydiscovery

Normal distributions are getting a little paranormal this October… #SciHumour

Happy Friday! 🎉 Every week, our team celebrates with a "happy hour" to unwind and wrap up a successful week together. Cheers to teamwork! #RapidNovor #HappyHour #TeamWorkMakesDreamsWork

🔬 How can we trust data if we can't trust the quality of the antibodies used? It's well known that many commercial antibodies don’t recognize their intended targets, but the true scale of the problem remains unclear. A study by Riham Ayoubi, Joel Ryan, Michael Biddle , and Carl Laflamme tackled this issue by evaluating 614 commercial antibodies against 65 neuroscience-related proteins across Western blot, immunoprecipitation, and immunofluorescence applications. Here’s what they found:   • Over 50% of antibodies failed in one or more applications.  • 50–75% of the protein set had at least one high-performing antibody, depending on the application, showing significant coverage of human proteins.  • Recombinant antibodies outperformed monoclonal and polyclonal options. Many of these underperforming antibodies have been widely used in published research—raising serious concerns. To address this antibody crisis, we need standardized characterization methods, with sequence-defined recombinant antibodies as a key solution for reliable tool antibodies. ❓ Have you experienced antibody failures in your research? Check out their paper here: https://lnkd.in/eBnSV4aa #ResearchReproducibility #ReproducibilityCrisis #AntibodyResearch 

Ever had some wild-looking Western blots or strange IF images? 👻 We could blame the science ghosts… or maybe our antibodies aren’t as reliable as we think! Share your spookiest research images for a chance to win a $100 gift card! Whether it’s a creepy gel, a bizarre blot, or an eerie microscopy photo, we want to see your most spine-chilling submissions. 🎃 Winners will be voted on and announced in our upcoming Halloween webinar! Submit your spooky science photos here: https://hubs.li/Q02RQ-q10

Join us for our upcoming webinar on Unmasking Antibody Reproducibility in Life Sciences! 🎃Thursday, October 31, 2024  ⌚11:00AM EST 📍Zoom In this webinar, we will learn:  • How mAb irreproducibility could unknowingly impact your research outcomes • Proven strategies to mitigate reproducibility risks when using research reagents • The role of antibody sequencing in ensuring reproducibility with mAbs Register below! #AntibodyReproducibility #AntibodyCrisis #ResearchReproducibility #LifeScienceResearch

On Sunday, our team came together in Kitchener, Ontario and walked in the annual Myeloma March organized by Myeloma Canada | Myélome Canada We are proud to announce that we raised a total of $2280 for multiple myeloma research efforts. Thank you to everyone for your donations and support! With more awareness and more research, we can all help provide the people living with this disease with the best standard of care, so they can enjoy more moments with their friends and families. #MakeMyelomaMatter #MultipleMyelomaMarch

Join us this Sunday, September 29th at Waterloo Park for the Multiple Myeloma March with Myeloma Canada | Myélome Canada! #MakingMyelomaMatter #MultipleMyeloma #BloodCancerAwarenessMonth

Unlike antagonistic antibodies that block targets, agonistic antibodies activate critical pathways, restoring or enhancing essential functions. Here’s how they work: 🔹 Signal Pathway Activation – Mimic natural ligands to trigger immune or metabolic responses. 🔹 Immune System Activation – Boost immune cells or modulate checkpoints to fight cancer. 🔹 Cell Death or Proliferation – Induce cell death in cancer or promote survival in critical conditions like ischemic injury. Despite their potential, only one agonist antibody—sotigalimab—has received FDA approval. Why is the development of these therapeutics lagging? Read our article on the challenges and strategies in developing agonist antibodies: https://hubs.li/Q02R3BFV0 #AntibodyTherapeutics #AgonistAntibodies #Biotech #Immunology #AntibodyDevelopment

👋 Hey, Toronto! Catch us at Booth #31 in the MaRS Discovery District for Biotech Connect Inc. this Thursday, September 26th! Stop by to chat with our team about the power of antibody sequencing, pick up some swag, and enter our 👻 Spooky Science 👻 contest for a chance to win $100! #BiotechConnect #AntibodySequencing #TorontoScience